EMA Withdrawn: Trevaclyn (laropiprant;nicotinic acid) — Merck Sharp Dohme Ltd

View source ↗

Summary

Trevaclyn (laropiprant; nicotinic acid) has been withdrawn from the market by Merck Sharp & Dohme Ltd for dyslipidemias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• Trevaclyn
• laropiprant; nicotinic acid (laropiprant; nicotinic acid)

Snippet

Status: Withdrawn. Therapeutic area: Dyslipidemias. MAH: Merck Sharp Dohme Ltd. Decision date: 10/04/2013